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ABSTRACT 
 Historically, women as subjects have been underrepresented in clinical research. 
Due to this problem, legislation was enacted by Congress in 1993 to require inclusion of 
women in NIH funded clinical trials. Female animals are also underrepresented in 
preclinical research and need to be included to ensure safe and effective drugs. Studies 
exclude female mammals under the assumption that the estrus cycle contributes to 
variability (Beery, 2011). This notion has been contradicted by several studies 
(Prendergast, 2014; Becker, 2016). New requirements of NIH funded researchers to 
consider sex as a basic biological variable were announced in 2014 (Clayton, 2014). As 
of June 5. 2016, all NIH grant applications must include plans to use equal numbers of 
both sexes and to perform statistical analysis for possible sex differences (NIH, 2016).  
This study examined the impact that these requirements have had on the inclusion 
of both sexes and the analysis of sex differences in preclinical research. The fields of 
neuroscience, pharmacology, and immunology were chosen for analysis based on 
research indicating that they had the lowest rates of analyzing sex differences prior to the 
mandate (Beery, 2011). A significant increase in the inclusion of both sexes was found in 
all fields (p<0.001), along with a 3.58 fold increase in the proportion of articles that 
analyzed sex differences. NIH funded pharmacology research was more likely to include 
both sexes and report sex difference analyses post-mandate. However, articles still must 
analyze sex differences and include both sexes at a much higher rate than the current 
2018 statistics calculated in this analysis (16.4% and 36.4%).Due to the recentness of the 
mandate, it is recommended that a follow-up study be conducted. The increases in female 
inclusion and sex differences analysis are promising signs of future improvement.
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INTRODUCTION 
Historically, female mammals are excluded from preclinical research due to the 
assumption that results from males apply to females, and concerns that hormonal cycles 
increase variability in samples and confound experimental manipulations (Beery, 2011). 
It is not only female animals that have been historically excluded from research. In 1977, 
the FDA advised the exclusion of women of child bearing age from drug trials due to 
possible effects of experimental medications on fertility and pregnancy (US Food and 
Drug Administration). These recommendations led to underrepresentation of women in 
clinical research for decades (Beery, 2011). Of drugs withdrawn from the US market 
from 1997–2000, the US Government Accountability Office reported that 8 out of 10 
drugs taken off the market had greater adverse effects in women (Simon, 2005). Without 
proper representation of women and female animals in research, the general public is put 
at risk. 
The notion of the 78 kg white man as the norm for research is harmful to women 
and minorities. For example, crash test dummies have been based off the biometrics to 
the average male for the past thirty years (Bose, 2011). As a result, seat-belted women are 
47 percent more likely to have serious injuries in accidents (Bose, 2011). Basing research 
off of just men has also led to bias in the way that female patients are diagnosed in 
diseases like coronary heart disease (CHD) and Attention-Deficit/Hyperactivity Disorder 
(ADHD) (Mikhail, 2005;Walters, 2018). In women, coronary heart disease presents 
differently than the clinical symptoms that have been classified in men (Mikhail, 2005). 
CHD kills an equal or higher percentage of women compared to men, yet the general 
public still refers to heart health as a predominantly male disease (Mikhail, 2005). 
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Sources also indicate that up to three quarters of women and girls with ADHD go 
undiagnosed due to symptoms mischaracterized as laziness or introversion (Walters, 
2018). 
 The bias of using men as a model for human disease has also affected the dosage 
of certain drugs and vaccines (Klein, 2016). Legislation has been in place to increase 
diversity in US clinical trials since the 1993 NIH Revitalization Act passed by Congress. 
This legislation has caused the proportion of women in clinical trials to increase to 50% 
(Beery, 2011). Likewise, as new rules such as the NIH mandate are instituted the hope is 
that female animal representation in preclinical research will reach 50 percent. The plan 
to enforce these rules revolves around data mining techniques by the NIH. The NIH aims 
to keep researchers accountable by monitoring when studies do not include both sexes or 
analyze sex differences; however, no repercussions for this have been indicated (Clayton, 
2014). If the mandate is not enough to increase female inclusion, it may be recommended 
that legislation be enacted. 
In May 2014, the National Institutes of Health announced that the agency planned 
to ensure that investigators account for sex as a basic biological variable (SABV) in NIH-
funded preclinical research (Clayton, 2014). As of June 2016, all NIH grant applications 
must include plans to use equal numbers of each sex and to perform statistical analysis 
for possible sex differences (NIH, 2016). This mandate was influenced by a 2011 meta-
analysis which revealed a male bias in 8 out of 10 biological disciplines (Beery, 2011).  
To address the issue of underrepresentation of female animals and analyze the effects of 
the NIH mandate, a meta-analysis of the most disparate biomedical fields was conducted. 
The fields of neuroscience, pharmacology, and immunology were chosen for analysis 
  
 
 3 
based on research indicating that they had the lowest rates of analyzing sex differences 
prior to the mandate (Beery, 2011). It was hypothesized that research funded by the NIH 
would be more inclusive of sex and have a larger increase in the inclusion of females than 
research with other sources of funding. 
The plan to include sex as a basic biological variable (SABV) in all grant 
applications was officially implemented for the fiscal year of 2017. The SABV policy 
requires researchers to factor sex into the design, analysis, and reporting of vertebrate 
animal and human studies (NIH, 2016). This meta-analysis aimed to assess the current 
state of sex inclusion in biomedical research. Three of the previously most disparate 
disciplines identified by Beery (2011) were analyzed: immunology, pharmacology, and 
neuroscience. According to data from 2009, these three disciplines analyzed for sex 
differences less than ten percent of the time, the least out of ten biomedical fields 
analyzed (Beery, 2011). Furthermore, males were specified in 65 percent of 
pharmacology articles while females were included in only 20 percent, with 15 percent of 
articles not specifying sex (Beery, 2011). Less than 10 percent of articles in these fields 
analyzed sex differences (Beery, 2011). Articles in immunology use only females more 
often than only males. Over 60 percent of articles did not specify what sexes were used 
(Beery, 2011). For neuroscience, 25 percent of articles did not specify sex and 55 percent 
of articles used only males (Beery, 2011).  
The consequence of using only one sex in preclinical research is that important 
differences between male and female organisms are being neglected. Estrogen and 
testosterone play important roles in both sexes’ bodies, however the levels and roles of 
these hormones are different between men and women. For example, in males 
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testosterone is first converted into estradiol by aromatase to masculinize the brain. 
Estrogen affects a wide variety of processes including neuronal differentiation and innate 
immunity. Due to the effects of estrogen, women have more reactive innate immune 
systems than men, leading to more adverse reactions to vaccines (Klein, 2016).  
The pressure on researchers to produce statistically significant results may have 
an impact on how they approach the topic of choosing animals to include in their 
analysis. Some have argued that using only male animals increases reproducibility due to 
the estrus cycle of female mammals possibly adding variance in results. This notion has 
been contradicted by four studies of mice and rats (Becker, 2016; Prendergast, 2014; Itoh, 
2015; Meziane, 2007). A meta-analysis of neuroscience articles indicated that studies that 
used both male and female rats, with no regard to estrus staging, were no more variable 
than studies that used only males (Becker, 2016). P values ranged from 0.6 to 0.95 when 
conducting a standard t-test on the trait variance of neurobehavioral measures in males 
versus females (Becker, 2016). 
A meta-analysis of whether monitoring the estrous cycle reduces variability of 
results found that females at any point in estrus were no more variable than males. This 
opposes the idea that if females are included in research, they need to be studied at the 
four different phases of estrous (Prendergast, 2014). This study also found that group 
housing increased trait variability by 37 percent. This is a much larger amount of 
variability added to experimental designs than including both sexes. Furthermore, it 
should be noted that individual differences create variability in experimental results. 
Studying both sexes is just one way to increase the generalizability to a population. For 
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example, when studying certain antidepressants in males, the results do not have any 
predictive relevance to the clinical outcomes of females (Koren, 2014).  
Lastly, a meta-analysis of microarray gene expression datasets (5 million probes), 
found that in both mice and humans females were very slightly less variable than males 
(Itoh, 2015). However, when looking a tissue specific microarrays, males were more 
variable in spleen tissue and females were more variable in adrenal tissue. These findings 
support the opinion that one sex is not more variable than the other. On the contrary, sex 
differences are ubiquitous and need to be examined on a molecular, cellular and 
organismal level.  
Sex-based differences in disease are consequences of X chromosome inactivation, 
differences in quantities of hormones, and differences in anatomy. Immunology may be 
the field with the most pronounced sex differences out of the three. There are 60 known 
genes carried on the X chromosome that are involved in immune regulation (Klein, 
2016). X chromosome inactivation likely is the largest factor when it comes to sex 
differences in immunity (Klein, 2016). Females have higher expression of genes on the 
X-chromosome which include immune markers like FoxP3 and CD40L. Females produce 
higher Th2 response and antibodies. This leads to better protection from infections but 
their hyperimmune responses increase susceptibility to autoimmune diseases (Taneja, 
2018).  
Klinefelter’s syndrome, which occurs when males have an extra X chromosome, 
leads to many immunological changes. This condition results in low testosterone, 
increased gonadotrophins, and elevated estrogen concentrations (Ko’ar, 2000). Due to 
these hormonal and cellular differences, men with Klinefelter’s syndrome respond with 
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higher immunoglobulin concentrations, CD4+ T cell numbers, CD4/CD8 T cell ratios, 
and B cell numbers than XY males (Ko’ar, 2000). Furthermore, the immunological 
effects of Klinefelter’s syndrome are reversed by testosterone therapy. This illustrates the 
important role of hormones in immunity. Moreover, women with Turner syndrome 
(nondisjunction error resulting in X0 instead of XX) have lower IgG and IgM levels and 
lower T cell and B cell levels compared to XX females (Klein, 2016). Interestingly, both 
patients with Klinefelter’s syndrome and patients with Turner syndrome show increased 
development of autoimmune disease. This illustrates the major role of the X chromosome 
in susceptibility to autoimmune diseases (Klein, 2016). Estrogen also plays a major role 
in autoimmune diseases such as Grave’s disease, systemic lupus erythematosus, and 
multiple sclerosis (Klein, 2016). 
In general, both the proportion of individuals infected and the severity of infection 
are higher in males than females for viral, bacterial, fungal, and parasitic diseases (Klein, 
2016). Pro-inflammatory cytokine responses, T cell proliferation, and antibody responses 
are also greater in female mice than male mice (Klein, 2016). Furthermore, there are 
variations in estrogen and progesterone levels during the different phases of the menstrual 
cycle. These hormones influence t-helper 1, t-helper 2, and t- regulatory cell populations. 
T-reg and TH2 cells are associated with peaks in estrogen while TH1 cell levels drop 
during estrogen peaks (Klein, 2016). However, predictable hormonal changes do not 
make females any more variable than males (Becker, 2016). The sex differences in 
immunology are diverse and ubiquitous throughout the body. Research on both sexes is 
imperative to fully understand these differences.  
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Sex differences exist in every part of the brain, including the hippocampus, 
amygdala, and neocortex (Andreano, 2009). Functional cerebral asymmetries are more 
common in males than in females, meaning that functions such as speech or facial 
recognition are lateralized to one side (Killgore, 2001). When men perceive happy faces 
versus fearful faces, amygdala activation is lateralized to either side according to fMRI 
data. However, when women see the same image there is no significant difference in the 
areas of the amygdala activated (Killgore, 2001). 
It is no secret that there are psychosocial, language, and memory differences 
between men and women (Andreano, 2009). Although some of these differences can be 
attributed to hormones, there are ubiquitous sex differences throughout the nervous 
system, from the anatomical to subcellular level. The gonadal steroid estrogen has been 
shown to affect neuronal growth, differentiation and survival at every point in 
development (Abel, 2010). Research has also shown that estrogen protects cortical 
neurons from glutamate toxicity (Singer, 1996).   
 The male brain is masculinized by testosterone being converted to estradiol and 
then crossing the blood brain barrier. Mechanisms for sex differences in the brain have 
been proposed for both hormonal and molecular factors. Sex differences have been found 
at the transcriptional level in zebrafish brains (Lee, 2018). Brain aromatase, prostaglandin 
3a synthase, and prostaglandin reductase 1 are among the genes with sexually dimorphic 
expression patterns. Furthermore, seven mouse genes have been found to show 
differential expression between the developing brains of male and female mice at stage 
10.5 days post coitum (dpc), before any gonadal hormone influence (Dewing, 2003). It is 
believed that those genes are integral in brain sexual differentiation as determined by 
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chromosomal sex. While my meta- analysis focused on in-vivo sex differences, it is 
important to remember that sex differences can be apparent in in-vitro tissues and cell 
cultures as illustrated in the prior study.  
The consequences of failing to include sex-based differences in study design and 
analyses has effectively led to treatment regimens that are identical for both men and 
women. As a result of this bias, differences in drug efficacy and adverse effects 
reportedly led to the withdrawal of eight out of ten prescription drugs from the United 
States market in 2005, specifically owing to health issues in women (Simon, 2005). 
Critics of sex-specific analysis claim that conducting scientifically rigorous trials with 
enough statistical power to detect sex differences is inefficient in terms of time as well as 
cost. Nevertheless, when prescription drugs are withdrawn from the U.S. market because 
they cause greater health risks for women than men, the cost of not doing such analyses 
becomes a greater liability for drug companies. 
Arrhythmias due to atypical antipsychotics were found to be much more common 
in women (Aichhorn, 2007). According to the FDA’s good laboratory practices for 
preclinical research, which provides the basis for toxicity and dosing, it is not required 
that research be conducted on both sexes of animals to be brought to clinical trials. Only 
guidance for the ‘Animal Rule’—which allows experimental drugs to surpass the clinical 
trial process if it is unethical to test on humans—requires testing on both sexes. However, 
in the normal industry standards, there is no requirement for this. Not testing both sexes 
can lead to adverse outcomes in the understudied sex during and after the clinical trial 
process.  
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There are sex differences other than adverse effects caused by drugs. Differences 
in drug metabolism and absorption rate of certain drugs have been found. This has been 
hypothesized to be due to X chromosome inactivation of certain CYP genes, which play a 
major role in drug metabolism. The absorption rate and extent of a drug are drug-specific 
so it is difficult to pick out blanket mechanisms different in men and women. Examples 
of drugs that illustrate sex differences in drug absorption include, rifampicin, and IM 
cephradine (Soldin, 2009). Increased absorption of rifampicin is seen in women (Gorksi, 
2009). Lower bioavailability and absorption of intramuscular cephadrine was observed in 
women. Furthermore, it is postulated that women, due to possessing larger amounts of 
subcutaneous lipid content, receive different doses of transdermally administered drugs. 
Additionally, women have greater respiratory minute ventilation and lower tidal volume, 
which may result in decreased ingestion of inhaled aerosol drugs (Soldin, 2009). 
Female enterocytes express significantly different levels of CYP3A isoenzymes 
than males, which contribute the metabolism of many orally administered drugs (Soldin, 
2009). Drug rate of absorption is influenced by multiple factors, including gut transit 
times, lipid solubility and molecular weight of the drug, along with pH and motility of the 
gut. Gastric fluids are more acidic in males than females. Reduced pH results in 
decreased absorption of weak acids and increased absorption of weak bases. Transit times 
are significantly different in men and women. Mean transit times are shorter in men than 
in women; 44 hours compared to 92 hours (Soldin, 2009). It has also been found that 
studying the dosage of certain antidepressants in males is completely irrelevant to the 
clinical outcomes in females (Koren, 2014). Studying sex differences in all 
pharmacological studies could lead to better clinical outcomes for women.  
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In summary, a meta-analysis of three disparate fields identified by Beery was 
conducted. Neuroscience, immunology and pharmacology all have widespread sex 
differences which are worth analyzing in papers that are relevant to both men and 
women. It was hypothesized that the inclusion of both sexes and sex differences analysis 
would increase after the enactment of the mandate in 2016. Furthermore, it was expected 
that NIH funded research would include both sexes and analyze sex differences more 
often than research with other sources of funding. 
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METHODS 
Published papers in nine peer reviewed journals were evaluated for several 
variables (See Table 1). The fields neuroscience, pharmacology, and immunology were 
chosen to be the targets of the research based on Beery and Zucker’s 2011 paper 
illustrating that these three fields had the largest discrepancies in the use of female versus 
male animals. Three major journals from each field were selected for review. Then the 
choice was made to use solely mice papers because mice are the most common model 
organism for studying human disease (Spencer, 2002). Only papers dated from 2009 to 
2018 were used.  
Table 1: Number of Articles per Field 
Field Neuroscience Pharmacology Immunology 
Journals Neuron: 471 
 
Neuroscience: 357 
 
Nature Neuroscience: 258 
Journal of Medicinal Chemistry: 
229 
 
British Journal of 
Pharmacology: 81 
 
Neuropsychopharmacology: 169 
 
PloS Pathogens: 
324 
 
Vaccine: 169 
 
Nature 
Immunology: 275 
Total 1082 474 766  
 
Mice were chosen to be the organism of interest for this study due to immunology 
using primarily mice as subjects (Beery, 2011). Furthermore, the use of mice as a model 
organism has drastically risen since 1990. The mouse has surpassed the rat as the most 
popular animal model (Spencer, 2002). Because in this meta-analysis, there was 
particular attention paid to the role of hormones and their epigenetic consequences, 
studies sacrificing embryos and mice younger than 4 days old were not included in the 
analysis due to minimal sex characteristics present (Schlomer, 2013). Mice are altricial 
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which means that they do not start secreting hormones until after birth, unlike humans 
which sexually differentiate in-utero. Therefore, it can be assumed that most sex 
differences other than on the cellular level will not be apparent. It can also be inferred 
that embryonic research uses both sexes due to the lack of most defining sexual 
characteristics until postnatal day 4-5 (Schlomer, 2013). 
The following inclusionary and exclusionary criteria was then applied to the 
search (see Table 2). Data for the nine journals were mined from PubMed. A targeted 
search was performed to find articles that met the inclusionary and exclusionary criteria 
listed in Table 2. The search can be found in Appendix C. A program was written to 
extract the title, data, authors, and affiliation of the first author. Another program was 
written to separate American articles from international articles, in order to control for 
other policies that would affect the proportion of sexes used. After the valid articles’ 
information was imported into an excel sheet, each was analyzed by hand for possible 
excluding characteristics and for the three variables gathered.  
Table 2: Inclusionary and Exclusionary Criteria.  
Inclusionary Exclusionary 
• USA affiliated first author 
• Uses mice 
• Relevant to human health 
• In-vivo and ex-vivo experiments 
• Used animals other than mice 
• >90% one gender affected (i.e. breast 
cancer) 
• Conditions involving the gonads or 
genitals 
• X-linked conditions 
• BALB/c and Nu/Nu mice  
• Mice under 5 days old 
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The search was limited to the United States due to the NIH only funding US 
researchers. In-vivo and ex-vivo experiments were particularly of interest due to 
hormonal factors affecting cells being the primary reasoning of researchers to not use 
females. BALB/c mice were excluded due to unusual male aggression seen in that strain 
of mice leading to more females used. Nude mice were also excluded due to diminished 
reproductive capability of homozygous females, leading to more readily available female 
animals. Embryonic and neonatal mice under the age of P5 were excluded due to most 
sexual differentiation not starting until postnatal day 5 due to their lack of precocial 
hormone secretions.   
Papers that did not include any in-vivo experiments, studied diseases that affected 
primarily one gender, involved reproduction, involved X-linked diseases or mutations, or 
researched urogenital diseases were all excluded from the PubMed search. The search 
can be found in Appendix B along with the program used to extract data. The population 
of papers using mice from the last ten years in the 9 journals totaled 14,819 articles 
(Figure 1). The full population of biomedical research using mice between 2009 and 2018 
was narrowed down to 2322 articles across nine journals and 3 fields known for their 
disparate use of sexes (Figure 1). 
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Figure 1: Applications of Search Criteria. 
 
According to the NIH’s new policies: “Applicants must provide strong 
justification for applications proposing to study only one sex. Such justification may 
include the study of sex-specific conditions or phenomena (e.g., ovarian or prostate 
cancer), acutely scarce resources (e.g., non-human primates), or investigations in which 
the study of one sex is scientifically appropriate. The absence of evidence regarding sex 
differences in an area of research does not constitute strong justification to study only one 
sex.” These guidelines served as a basis for whether or not a study using only one sex 
would be included. Statements such as, “prior research showed that female animals 
consume more alcohol and therefore were excluded” were not considered to be valid 
justification. 
Due to availability of athymic mice and greater variation in group housed 
BALB/c male mice, immunology is generally biased to use more females. BALB/c mice 
are well known for their ability to produce plasmocytomas upon injection with mineral 
oil. This is a reliable way to study monoclonal antibodies. Because of this unique 
characteristic and the prevalence of abnormal male aggression skewing results, articles 
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using BALB/c strains were considered to have sound justification for using one sex and 
therefore were excluded from analysis.  
Furthermore athymic (nu/nu) mice were excluded from this study. This was due 
to the fact that all athymic nude females have extremely reduced reproductive capability. 
Moreover, the most humane way to study T cells requires the use of this particular breed 
of mice. In turn, this leads to a surplus of homozygous females to use because the most 
effective way to breed would require a homozygous male and a heterozygous female. 
This unfortunately limits the usefulness of data obtained in immunology due to two of the 
most commonly used strains being excluded. The results likely are skewed to favor more 
sex differences analyses and more inclusion of male mice in studies. The categorization 
of variables veered from Beery’s paper in that a definite cutoff was proposed for the use 
of sexes to be roughly equal rather than assuming equal representation if they used both 
sexes at all. A cutoff was also set for specification but this rarely mattered as most studies 
either specified sex for all of their experiments or for none at all (Table 3). Furthermore, 
the exact percentage of studies that did not uniformly use the same sexes throughout 
experiments is not available, but can be assumed to be roughly 8 percent of articles based 
on data from the journal Nature Neuroscience. 
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Table 3: Description of Variables Analyzed and Classification.  
Definition of Variables 
Variable Categorization Definition 
NIH 
Funding 
Yes/No Determined by the acknowledgement of such in the article. 
   
Analysis Yes/No Indicated that there were no observed sex differences or 
described statistical tests performed on sex 
   
Sex Male 
  
Used only males in 25% or more of the experiments and 
both sexes or unspecified in the other 75% 
Used males as controls and both as experimental animals or 
the opposite 
 Female Used only females in 25% or more of the experiments and 
both sexes or unspecified in the other 75% 
Used females as controls and both as experimental animals 
or the opposite 
 Both Used roughly equal parts males and females in more than 
75% of experiments 
Used mostly one sex but repeated the same exact study 
with a smaller N of the other sex 
 Unspecified Did not specify sex in more than 25% of experiment types 
and used both in the other experiments 
Unspecified in more than 75% of experiments and used 
only males or only females in in less than 25%   
 Other Any instances that did not fit the above categories. Such as, 
a study used males as controls and females as experimental 
animals  
 
For the large majority of articles (91.8 percent of Nature Neuroscience articles), 
the sexes used would be specified in the methods section and would be uniform 
throughout the study. A typical phrase found in the methods section would be: “Males 
and females were used throughout this study.” However, females sometimes were 
excluded for particular types of experiments such as behavioral measures. This is why 
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there was a need for a specific cutoff rather than marking a study as ‘both’ if it included 
both males and females at some point in the study.  
Table 3 describes the cutoff percentage of experiments that used both sexes for it 
to be considered approximately equal representation. The percentage of experiments as 
stated above was only based on experimental types, not the individual N of males and 
females. Only in-vivo experiments were included, if the study also performed in-vitro 
experiments. Note that the ‘other’ category only contained 10 out of 2322 articles, mostly 
within the pharmacology category.   
 Articles that met the inclusionary and exclusionary criteria analyzed for the 
following variables: NIH funding, what sexes were used, whether or not they analyzed 
for possible sex differences, and if they were published before or after the mandate. Chi-
square tests were performed in SPSS (Statistical Package for the Social Sciences by IBM) 
along with Pearson correlations in Excel.   
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RESULTS 
There have been significant improvements across fields in respect to reporting sex 
differences analyses and to including both males and females. Figure 2 illustrates the 
proportional differences in what sexes were used prior to the mandate versus how the 
proportions changed after it was issued. Neuroscience, immunology, and pharmacology 
all had significant increases in the amount of articles that used both males and females 
after the mandate was issued (p<0.001). Note that chi square statistical analyses were 
used. A limitation of this type of statistical test is that with a very large N, results may be 
reported as very significant with a relatively small change. 
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Figure 2: Proportion of Each Sex Used by Field Pre- versus Post-Mandate  
A. The figure indicates a significant increase in the use of both sexes in a given article 
(p<0.001) and a significant decrease in the amount of articles that do not specify sex 
(p<0.001). This data combines all three fields. B. In neuroscience there was a significant 
increase in the use of both sexes and a significant decrease in the amount of unspecified 
carticles (p<0.001). C. In pharmacology there was a significant increase in the amount of 
articles that used both males and females (p<0.001) D. There was also a significant 
increase in the use of both sexes in immunology (p<0.001).   
 
  
  
Figure 3: Percentage of Articles Analyzing Sex Differences 
A. This figure indicates the percentage of articles per field that analyzed sex differences. 
This is subdivided into prior to 2016, when the regulations enacted, and 2016-2018. 
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Immunology articles analyze sex differences at a significantly lower rate than 
neuroscience and pharmacology (p<0.001). Neuroscience and pharmacology both saw 
significant increases in the percentage of articles that analyzed sex differences while 
Immunology only increased by 1 percent.   
B. This graph only takes into account articles that specified that they used both sexes in 
roughly equal proportions. There isn’t a significant change overall or within neuroscience 
and immunology. However, pharmacology showed a remarkable increase in sex 
differences analyses after 2015 (p<0.001). Note that the percentages in B are proportional 
to the percentages in A. However the number of articles that used both males and females 
is smaller than the total within each field, thus increasing the percentages found in B.  
 
Figure 3 compares the proportion of articles that analyze sex differences prior to 
the mandate versus after its enactment. There was a significant increase in the overall 
number of articles that analyzed sex differences after the mandate (p<0.001) (Figure 3A). 
However, when looking only at articles that used both males and females, the percentage 
of articles that analyzed sex differences did not change in any field but pharmacology 
(p<0.001) (Figure 3B).  
The difference between 3A and 3B is that 3A analyzed all articles within a given 
field while 3B analyzes the subset of articles that are labeled as ‘both’. For example in 
neuroscience for 3A, 47/653 neuroscience articles published before 2016 analyzed sex 
differences and 57/ 429 articles published between 2016 and 2018 analyzed sex 
differences. Meanwhile in 3B, 44/122 articles that used both males and females analyzed 
sex differences articles prior to 2016. 54/186 articles that used both males and females 
analyzed sex differences in 2016 onward. It is speculated that the difference between 3A 
and 3B is due to the increase in proportion of articles that use both males and females in 
neuroscience (seen in figure 2B). The proportion of neuroscience articles labeled as 
‘both’ increased from 18.6% to 43.4% (Figure 2B). The overall increase in the percentage 
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of articles that used both sexes is strongly correlated with the increase in the overall 
percentage of articles that analyzed sex differences (r= 0.822).  
   
Figure 4: NIH funding Increased the Likelihood of Sex Differences Analysis and Sex 
Inclusion in Pharmacology 
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A. A slightly larger percentage of NIH funded neuroscience articles included both males 
and females. A significantly larger proportion of NIH funded pharmacology articles 
included both males and females (p=0.001) 
B. NIH funded studies had a larger amount of studies that analyzed sex differences in 
immunology (p>0.05) and pharmacology (p=0.005). However in neuroscience, the 
inverse was seen (p=0.014).  
 
It was hypothesized that NIH funding would affect the inclusion of sexes and 
analysis of sex differences. These relationships are indicated in Figure 4A and 4B. 
Pharmacology seems to be the field that was the most positively affected by the NIH 
mandate. In Figure 4B, significantly more NIH funded articles analyzed sex differences 
in pharmacology after the 2016 mandate (p= 0.001). This relationship was not seen for 
any field in articles published in 2009-2015 (not shown in a figure). However, for 
neuroscience a negative relationship was seen between NIH funding and sex differences 
analysis. This might be due to a much smaller number of articles lacking NIH funding in 
Neuroscience compared to the other two fields, especially post 2016. For Figure 4A, a 
slightly larger percentage of NIH funded neuroscience articles included both males and 
females. A significantly larger proportion of NIH funded pharmacology articles included 
both males and females (p=0.001).  
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Figure 5: Percentage of Articles that Analyzed Sex Differences per Year per Field 
The percentage of papers that analyzed for sex increased by 3.56 fold between 2015 and 
2018 and overall by 3.78 fold. There is a visible peak in sex differences analysis in 2012, 
the year after Beery’s publication, and there is also an increase in analysis in 2016, the 
year that the plan was announced. Sex analysis doubled in 2018 compared to 2017. 
However there was no overall change in the proportion of articles that used both sexes to 
analyze sex differences. The large increase in Figure 2A is likely due to a generalized 
increase in the use of both sexes.  
 
The percentage of papers that analyzed for sex increased by 3.56 fold between 
2015 and 2018 and overall by 3.78 fold, which can be seen in Figure 5. There is a visible 
peak in sex differences analysis in 2012, the year after Beery’s publication, and there is 
also an increase in analysis in 2016, the year that the mandate was enacted. Furthermore, 
sex analysis doubled in 2018 compared to 2017. The upward trend seen in Figure 5 
provides promise that there will be even more progress in the coming years as more 
articles affected by the mandate are published. It can be speculated that much of the 
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change seen after 2016 was done under researchers’ own volition rather than in 
accordance to the mandate. The large majority of research directly affected by the FY 
2017 regulations had not yet been published which indicates that researchers heard about 
the new mandate and followed it even if it was not directly applicable to their research.  
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DISCUSSION 
 In 1977, the FDA advised to exclude women of child bearing age from 
drug trials due to possible effects of experimental medications on fertility and pregnancy.  
These recommendations led to underrepresentation of women in clinical research into the 
1990’s. Prior to the NIH Revitalization Act in 1993, clinical trials were not required to 
study the effects of a medication on both men and women. After this Act was passed, 
inclusion of women has increased to fifty percent (Department of Health and Human 
Services, 2012). Of drugs withdrawn from the US market from 1997–2000, the US 
Government Accountability Office (GAO) reported that 8 out of 10 drugs taken off the 
market had greater adverse effects in women. The Food and Drug Administration does 
not require researchers to perform preclinical research on both sexes of animals to bring a 
drug to trial. This is an important topic to monitor as industries try to get the most 
significant results in the most cost effective manner.  
The NIH first announced plans to require researchers to analyze sex differences 
and include both sexes in 2014. The official requirements were rolled out June 5, 2016. 
Before this meta-analysis, there had not been a study that analyzed the relationship 
between National Institutes of Health funding and the inclusion of both sexes in 
preclinical research. Furthermore, a follow up to Beery’s 2011 paper analyzing sex 
inclusion across fields has not been published. This meta-analysis aimed to quantify the 
progress that has been made since Beery’s publication of 2009 data and define a 
relationship between government funding and sex difference analysis. It was 
hypothesized that there would be an increase in the inclusion of both sexes and increased 
analyses of sex differences over time. Furthermore, it was predicted that NIH funded 
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articles would be more likely to be inclusive of both sexes and analyze for sex 
differences.  
There are widespread sex differences in humans, many of which are conserved 
across species. It is important for scientists conducting preclinical research to take into 
account these differences when applying their research to humans. To understand the 
biology of women or develop safe treatments for diseases of women one must do more 
than study men and male animals. Pharmacology, immunology, and neuroscience in 
particular are fields with important sex differences that need to be studied.  
Studying sex differences is important for neuroscience due to their presence 
across cellular, anatomical, and behavioral levels. These differences include increased 
lateralization in males, differential gene expression independent of hormones in the brain, 
and neuroprotective effects of the gonadal steroid estrogen (Killgore, 2001; Cahill, 2006; 
Koren, 2014). Furthermore, women are predisposed to the neurodegenerative disease 
multiple sclerosis (MS) which falls under immunology and neuroscience (Klein, 2016). 
Estrogen has been hypothesized to play an important role in autoimmune diseases such as 
MS and Grave’s disease (Klein, 2016). Furthermore, women have more active immune 
systems which can lead to adverse effects of vaccines and other immunological drugs. In 
Pharmacology, many metabolism genes are differentially expressed based on cellular sex 
(Soldin, 2011). Lower gastric pH is also common in men which can contribute to 
enhanced or reduced drug absorption (Soldin, 2009). In summary, sex differences are due 
to X chromosome inactivation, anatomical differences, and exposure to different levels of 
sex hormones. The differences previously mentioned have the capacity to affect the 
health of women and men if they are not properly analyzed in preclinical research. 
  
 
 27 
According to the performed analyses, there was a significant overall increase in 
the number of articles that analyzed sex differences after 2015 (p<0.001, Figure 3A). 
However, when only including articles that included both sexes, there was only an 
increase in sex differences analyses for pharmacology (Figure 3B). Furthermore, there 
was an overall increase in the inclusion and specification of sexes (p<0.001). The 
inclusion of sexes and analysis of sex differences varied across the three examined fields.  
All fields showed significant improvements in the inclusion of both sexes after the 
mandate was enacted (Figure 2 A-D). Neuroscience also showed a significant increase in 
the number of articles that specified sex (Figure 2B). While it is promising that these 
fields have moved in the right direction in terms of sex inclusion, immunology still only 
included both sexes in 14.5 percent of research between 2016 and 2018 (Figure 2D). 
Neuroscience showed the largest improvement in inclusiveness, and used both sexes in 
42 percent of research between 2016 and 2018. 
Neuroscience and pharmacology improved in regard to sex differences analyses 
over time (Figure 5). The amount of articles that analyzed sex differences in these two 
fields doubled between 2017 and 2018. In respect to the proportion of articles that 
analyzed sex differences within the ‘both’ category, only pharmacology articles showed 
an improvement (p<0.001; Figure 3A-B).  
Immunology did not improve in respect to specification of sex or in analysis of 
sex differences even though the field has started to include more males. It is possible that 
because the field primarily uses females, researchers do not believe that the mandate 
applies to them. Furthermore, pharmacology was the only field that had an interaction 
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between NIH funding and the likelihood of analyzing sex differences and including both 
sexes post 2015 (Figure 4A and B; p<0.001). This could mean that pharmacology, in 
respect to sex analysis, was most affected by the mandate. 
While both pharmacology and neuroscience have improved dramatically in 
comparison to 2009, there is still a long way to go. For 2018, the overall rate of articles 
that analyzed for sex differences was only 16.4 percent. Increasing that statistic to near 
one hundred percent in relevant articles would be ideal. Furthermore, almost seventy 
percent of articles are still using either one sex or not specifying what sexes were used. 
This is unacceptable unless this statistic continues in the positive direction. The only 
current repercussion issued by the NIH is that grant applications will be rejected if they 
do not address sex differences in their proposed experimental design. I propose that 
further repercussions such as grant repayment, and future disqualification from funding 
should be taken if it is found that a researcher failed to address sex differences in their 
publication as it was stated in their grant application.  
Several limitations are present in this data. This meta- analysis only focused on 
papers that included in-vivo experiments. However, it is important to acknowledge 
cellular and genetic sex differences found in animals that are independent of hormones. 
Furthermore, while mice are the most commonly used model organism, many 
pharmaceutical companies use multiple species, leading to a possibly less representative 
population of articles. Mice also comprise fifty percent of the model organisms used, so 
this research may not be representative of the other half of preclinical research. Lastly, 
this analysis only accounts for two years after the implementation of the new NIH policy, 
so it is possible that research conducted prior to fiscal year 2017 is being published with 
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no requirements to include both sexes. Furthermore, several discrepancies in 2009 data 
were found between this meta-analyisis and Beery’s paper. According to her paper, the 
rate of specification of sex in 2009 was 75, 80, and 35 percent for neuroscience, 
pharmacology, and immunology respectively (Figure 8; Beery, 2011). My analysis 
resulted in a specification rate of 50, 75, and 40 for these fields in 2009. This is justifiable 
since hers study used more types of animals than just mice and a less strict classification 
system than the one used in this study (Beery, 2011). 
It was hypothesized that an increase in the inclusion of both sexes and sex 
differences analysis would increase after the enactment of the mandate in 2016. 
Furthermore, it was expected that NIH funded research would include both sexes and 
analyze sex differences more often than research with other sources of funding. All fields 
did significantly increase in the proportion of articles that used both sexes post-mandate 
(Figure 2; p<0.001). No relationship was found between NIH funding and sex differences 
analysis or sex inclusion in immunology. For pharmacology, the presence of NIH funding 
post 2015, increased the likelihood that a given article would analyze sex differences and 
include both sexes (Figure 4A-B). This relationship was not seen in pharmacology for 
articles published between 2009 and 2015. This finding supports the hypothesis that an 
increase in sex differences analysis and sex inclusion would be seen after the mandate’s 
enactment.  
While there were significant improvements seen in the three fields studied, it 
should be noted that the mandate itself reflects requirements for grants rather than papers 
published. Furthermore, most research funded by grants accepted during the fiscal year of 
2017 has not been published yet. It could be that the improvements seen throughout the 
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years are due to a changing opinion within the scientific community of studying sex 
differences. This is supported by the finding that more research funded by other sources 
than the NIH in the field of neuroscience analyzed sex differences post 2015 (Figure 4B). 
If the new results are due to a changing environment, hopefully in the coming years, as 
more research directly affected by the mandate is published, there will be even larger 
increases in sex differences analyses and sex inclusion.  
In conclusion, there are many widespread sex differences present in the fields of 
pharmacology, immunology, and neuroscience. In order to ensure proper medical 
treatment of women, these differences should be addressed in preclinical research. This 
analysis indicates that the number of articles that use both sexes in their research has 
increased since the implementation of the new policies. There have also been increases in 
the specification of sex and the analysis of sex differences. The current statistics of 
articles analyzing sex differences (16.4 percent), and articles including both sexes (36.4 
percent) are unacceptable and need to increase in the coming years. A positive trend 
could continue into 2019 and beyond, due to the fact that researchers funded in 2016 and 
after likely have not yet published their research. It is possible that there could be a 
significant uptick in articles using both sexes in the coming years. This should be 
monitored and it is recommended that a similar study be conducted by 2022.  
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APPENDIX A: SUPPLEMENTAL FIGURES 
 
 
Figure 6: Proportion of Sexes used per Year across all Fields 
Indicates the proportion of sexes used each year across fields. 
  Male Female Both Unspecified Other 
Male 1     
Female -0.57951 1    
Both 0.596579 -0.78454 1   
Unspecified -0.76486 0.685571 -0.95563 1  
Other 0.243499 -0.27744 0.113465 -0.15736 1 
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A.  
B.  
C.  
Figure 7: Percentage of Sexes used per Field 2009-2018. 
A. Neuroscience has increased in specification by 40 percent while increasing the 
inclusion of both sexes by the same amount. B. There has been a slight increase in the 
amount of articles that used both sexes in Immunology. C. The inclusion of both sexes 
increased by 25 percent between 2015 and 2018. 
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(Taken from Annaliese Beery: Sex bias in neuroscience and biomedical research.) 
Figure 8: Beery 2009 Data by Field 
Data from 2009 indicated that immunology analyzed sex differences less than 5 percent 
of the time while neuroscience and pharmacology analyzed them at rates of 20 and 30 
percent. 
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APPENDIX B: SUPPLEMENTAL METHODS 
Search conducted on PubMed: 
 
("mice"[Mesh terms] OR "mouse"[All Fields] OR "mice"[All fields] NOT "Genetic 
Diseases, X-Linked"[MeSH Terms] AND ("2009/01/01"[PDAT] : "2018/12/31"[PDAT]) 
NOT "In-vitro Techniques"[mesh terms] NOT "Genitalia"[mesh terms] NOT 
"breast"[mesh terms] NOT Review[ptyp] NOT "Reproduction"[mesh terms] NOT 
"veterinary"[all fields] NOT "Genetic Diseases, Y-Linked"[Mesh terms] NOT 
"Embryo"[all fields] NOT "Female Urogenital Diseases"[mesh terms] NOT "Mental 
Retardation, X-Linked"[mesh terms] NOT "Male Urogenital Diseases" NOT "Herpes 
Genitalis"[mesh terms] NOT "Alphapapillomavirus"[mesh terms] AND 
("USA"[affiliation] OR "United States"[Affiliation] OR United States of 
America[Affiliation]) NOT "Animal Diseases"[mesh terms] AND "loattrfull text"[sb]  
NOT Cercopithecidae NOT Artiodactyla NOT Carnivora NOT Cetacea NOT 
Lagomorpha NOT Perissodactyla NOT Guinea Pigs NOT Chinchilla NOT Cuniculidae 
NOT Rats NOT Gerbillinae NOT Mole Rats NOT Myoxidae NOT Octodon NOT 
Porcupines NOT Sciuridae NOT Chiroptera NOT scandentia NOT Sirenia NOT Hyraxes 
NOT Insectivora NOT Marsupialia NOT Monotremata NOT Proboscidea Mammal NOT 
Xenarthra NOT Birds NOT Amphibians NOT Fishes NOT Reptiles NOT Invertebrates 
NOT Chlamydia NOT hamsters NOT rabbit NOT dog NOT cat NOT maternal NOT 
HPV NOT "Mice, Inbred BALB C"[Mesh terms] NOT Mice, Nude) AND "Plos 
pathogens"[Journal] 
 
Program 
 
The following is the program that was written to extract the following from the results of 
the above PubMed search: title, first author, first author affiliation, year of publication of 
each article. The articles were then grouped into USA affiliated and non-USA affiliated 
first authors, only the former was used in analysis.  
 
%% Written by:      Phoenix Throckmorton 
%%Purpose: This script will load string data from a .txt file and 
extract 
%%important information. This information will be filtered and 
organized 
%%into an excel spread sheet for presentation. 
tic 
%The script is organized as follows: 
%   1. INPUT VARIABLES 
%   2. Variable Allocation 
%   3. Extracting Data 
%   4. Post Processing 
%   5. Outputting Data 
clear all; 
close all; 
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%% 1.INPUT VARIABLES (Edit this) 
%%Change these as needed. Do not edit any other part of the script 
  
%enter directory where ALL files are located: 
file_directory = 'C:\Users\pthro\Desktop\NicolesProgram'; 
  
%enter name of .txt file, including .txt extension 
txt = 'Neuron.txt'; 
  
%enter the name of the exporting excel spreadsheet, including .xlsx 
%extension 
excel = 'USA_Neuron.xlsx'; 
  
%enter the name of the NON USA exporting spreadsheet, including .xlsx 
NONUSA_excel = 'NONUSA_Neuron.xlsx'; 
  
%% 2.Variable Allocation 
%This section opens files and prepares/converts variables for data 
transfer 
  
%set appropriate file directories and names 
cd(file_directory); 
txt_full = strcat(file_directory, '\', txt); 
excel_full = strcat(file_directory, '\', excel); 
  
%Prepares the .txt for file extraction, string by string 
ID = fopen(txt_full); 
data = textscan(ID, '%s'); 
size = length(data{1}); 
  
%%Preallocate other variables for data extraction 
  
%%title 
%counts how many times the initialization and termination terms occur 
initial_title_count = 0; 
final_title_count = 0; 
%keeps track of the indices for each occurence 
title_index = 0; 
  
%%year 
%counts how many times the initialization and termination terms occur 
initial_year_count = 0; 
final_year_count = 0; 
%keeps track of the indices for each occurence 
year_index = 0; 
  
%%firstname 
%counts how many times the initialization and termination terms occur 
initial_firstname_count = 0; 
final_firstname_count = 0; 
%keeps track of the indices for each occurence 
firstname_index = 0; 
  
 
 39 
  
%%lastname 
%counts how many times the initialization and termination terms occur 
initial_lastname_count = 0; 
final_lastname_count = 0; 
%keeps track of the indices for each occurence 
lastname_index = 0; 
  
%%affiliation 
%counts how many times the initialization and termination terms occur 
initial_affiliation_count = 0; 
final_affiliation_count = 0; 
%keeps track of the indices for each occurence 
affiliation_index = 0; 
  
%% 3.Extracting data Index 
  
%get the locations of all of the article titles, year, first name, last 
%name, and affiliation 
  
%This loop is performed first since only one instance of each term 
appears 
%for each article 
for i = 1:size 
     
   %check if an article title is to be shown, and save bounds 
    if contains(data{1}{i},'<ArticleTitle>') == 1 
        initial_title_count = initial_title_count + 1; 
        title_index(initial_title_count,1) = i; 
    end 
     
    if contains(data{1}{i},'</ArticleTitle>') == 1 
        final_title_count = final_title_count + 1; 
        title_index(final_title_count,2) = i; 
    end 
     
    %check if year is to be shown, and save bounds 
    if contains(data{1}{i},'<PubDate>') == 1 
        initial_year_count = initial_year_count + 1; 
        year_index(initial_year_count,1) = i; 
    end 
     
    if contains(data{1}{i},'</PubDate>') == 1 
        final_year_count = final_year_count + 1; 
        year_index(final_year_count,2) = i; 
    end  
end 
  
%initialize synchronization counters for initial and final bounds 
size_sync = length(year_index(:,1)); 
  
  
%now that the total number of articles is known, run through again 
between 
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%each bound and grab the first author and affiliation and pair them 
for j = 1:size_sync 
    if j == size_sync 
        loop_condition = size;   %prevents strange behavior at end of 
loop 
    else 
        loop_condition = title_index(j+1,1); 
    end 
     
    %check if author lastname is to be shown, and save bounds 
    for k = title_index(j,1): loop_condition 
        if contains(data{1}{k},'<LastName>') == 1 
            initial_lastname_count = initial_lastname_count + 1; 
            lastname_index(initial_lastname_count,1) = k; 
        end 
        if contains(data{1}{k},'</LastName>') == 1 
            final_lastname_count = final_lastname_count + 1; 
            lastname_index(final_lastname_count,2) = k; 
            break; %TERMINATES AFTER FIRST OCCURENCE 
        end 
    end 
     
    %check if author firstname is to be shown, and save bounds 
    for k = title_index(j,1): loop_condition 
        if contains(data{1}{k},'<ForeName>') == 1 
            initial_firstname_count = initial_firstname_count + 1; 
            firstname_index(initial_firstname_count,1) = k; 
        end 
       
        if contains(data{1}{k},'</ForeName>') == 1 
            final_firstname_count = final_firstname_count + 1; 
            firstname_index(final_firstname_count,2) = k; 
            break %TERMINATES AFTER FIRST OCCURENCE 
        end 
    end 
     
    %check if affiliation is to be shown, and save bounds 
    for k = title_index(j,1): loop_condition 
        if contains(data{1}{k},'<AffiliationInfo>') == 1 
            initial_affiliation_count = initial_affiliation_count + 1; 
            affiliation_index(initial_affiliation_count,1) = k; 
        end 
  
        if contains(data{1}{k},'</AffiliationInfo>') == 1 
            final_affiliation_count = final_affiliation_count + 1; 
            affiliation_index(final_affiliation_count,2) = k; 
            break %TERMINATES AFTER FIRST OCCURENCE 
        end 
    end 
     
     
end 
  
%do a second pass to truly filter out the year locations 
for j = 1:size_sync 
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    for k = year_index(j,1): year_index(j,2) 
        if contains(data{1}{k},'<Year>') == 1 
            year_index(j,1) = k; 
        end 
         
        if contains(data{1}{k},'</Year>') == 1 
            year_index(j,2) = k; 
        end 
    end 
end 
  
%%3.B Raw Data Extraction 
%Grab the data using the determined indeces 
  
%preallocate data storing variables based on now known number of 
articles 
title = strings(size_sync,1);  
year = strings(size_sync,1);  
first = strings(size_sync,1);  
last = strings(size_sync,1);  
affiliation = strings(size_sync,1);  
institution = strings(size_sync,1); 
  
for j = 1:size_sync 
    %For article titles 
    for k = title_index(j,1): title_index(j,2) 
       title(j) = strcat(title(j),{' '},data{1}{k}); %adds the entire 
title line 
    end 
    %For years 
    for k = year_index(j,1): year_index(j,2) 
       year(j) = strcat(year(j),{' '},data{1}{k}); %adds the entire 
year line 
    end 
    %For lastnames 
    for k = lastname_index(j,1): lastname_index(j,2) 
       last(j) = strcat(last(j),{' '},data{1}{k}); %adds the entire 
lastname line 
    end     
    %For firstnames 
    for k = firstname_index(j,1): firstname_index(j,2) 
       first(j) = strcat(first(j),{' '},data{1}{k}); %adds the entire 
firstname line 
    end     
    %For affiliations 
    for k = affiliation_index(j,1): affiliation_index(j,2) 
       affiliation(j) = strcat(affiliation(j),{' '},data{1}{k}); %adds 
the entire affiliation line 
    end 
     
    %Determination of university 
    if contains(affiliation(j), 'inc.') || 
contains(affiliation(j),'incorporated') ... 
            || contains(affiliation(j), 'Inc.') || 
contains(affiliation(j), 'corporation') ... 
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            || contains(affiliation(j), 'Corporation') 
         
        institution(j) = 'Biotech'; 
    elseif contains(affiliation(j), 'Hospital') 
        institution(j) = 'Hospital'; 
    elseif contains(affiliation(j), 'University') 
        institution(j) = 'University'; 
    else 
        institution(j) = ' '; 
    end 
end 
  
  
%% 4.Post Processing 
  
%%Remove any articles that were published outside of the US 
  
%preallocate based on total files 
junk_title = strings(size_sync,1);  
junk_year = strings(size_sync,1);  
junk_first = strings(size_sync,1);  
junk_last = strings(size_sync,1);  
junk_affiliation = strings(size_sync,1);  
junk_institution = strings(size_sync,1); 
NONUSA_counter = zeros(size_sync,1); 
  
%Remove any information that is not desired for the final output 
  
%for title 
title(1:size_sync) = erase(title(1:size_sync), ' <ArticleTitle>'); 
title(1:size_sync) = erase(title(1:size_sync), '<ArticleTitle> '); 
title(1:size_sync) = erase(title(1:size_sync), '<ArticleTitle>'); 
title(1:size_sync) = erase(title(1:size_sync), ' </ArticleTitle>'); 
title(1:size_sync) = erase(title(1:size_sync), '</ArticleTitle> '); 
title(1:size_sync) = erase(title(1:size_sync), '</ArticleTitle>'); 
  
%for first name 
first(1:size_sync) = erase(first(1:size_sync), ' <ForeName>'); 
first(1:size_sync) = erase(first(1:size_sync), '<ForeName> '); 
first(1:size_sync) = erase(first(1:size_sync), '<ForeName>'); 
first(1:size_sync) = erase(first(1:size_sync), ' </ForeName>'); 
first(1:size_sync) = erase(first(1:size_sync), '</ForeName> '); 
first(1:size_sync) = erase(first(1:size_sync), '</ForeName>'); 
  
%for lastname 
last(1:size_sync) = erase(last(1:size_sync), ' <LastName>'); 
last(1:size_sync) = erase(last(1:size_sync), '<LastName> '); 
last(1:size_sync) = erase(last(1:size_sync), '<LastName>'); 
last(1:size_sync) = erase(last(1:size_sync), ' </LastName>'); 
last(1:size_sync) = erase(last(1:size_sync), '</LastName> '); 
last(1:size_sync) = erase(last(1:size_sync), '</LastName>'); 
  
%for year 
year(1:size_sync) = erase(year(1:size_sync), ' <Year>'); 
  
 
 43 
year(1:size_sync) = erase(year(1:size_sync), '<Year> '); 
year(1:size_sync) = erase(year(1:size_sync), '<Year>'); 
year(1:size_sync) = erase(year(1:size_sync), ' </Year>'); 
year(1:size_sync) = erase(year(1:size_sync), '</Year> '); 
year(1:size_sync) = erase(year(1:size_sync), '</Year>'); 
  
%for affiliation 
affiliation(1:size_sync) = erase(affiliation(1:size_sync), ' 
<AffiliationInfo>'); 
affiliation(1:size_sync) = erase(affiliation(1:size_sync), 
'<AffiliationInfo> '); 
affiliation(1:size_sync) = erase(affiliation(1:size_sync), 
'<AffiliationInfo>'); 
affiliation(1:size_sync) = erase(affiliation(1:size_sync), ' 
</AffiliationInfo>'); 
affiliation(1:size_sync) = erase(affiliation(1:size_sync), 
'</AffiliationInfo> '); 
affiliation(1:size_sync) = erase(affiliation(1:size_sync), 
'</AffiliationInfo>'); 
affiliation(1:size_sync) = erase(affiliation(1:size_sync), ' 
<Affiliation>'); 
affiliation(1:size_sync) = erase(affiliation(1:size_sync), 
'<Affiliation> '); 
affiliation(1:size_sync) = erase(affiliation(1:size_sync), 
'<Affiliation>'); 
affiliation(1:size_sync) = erase(affiliation(1:size_sync), ' 
</Affiliation>'); 
affiliation(1:size_sync) = erase(affiliation(1:size_sync), 
'</Affiliation> '); 
affiliation(1:size_sync) = erase(affiliation(1:size_sync), 
'</Affiliation>'); 
  
for j = 1:size_sync 
    %check to see if the article is US affiliated 
    if contains(affiliation(j), 'USA') || contains(affiliation(j), 
'United States') 
     
    else %keeps track of where non US files are 
        NONUSA_counter(j) = 1; 
    end 
end 
  
%determines where NONUSA Data occurs 
c = 0; 
for j = 1:size_sync 
    if NONUSA_counter(j) == 1 
        c = c + 1; 
        NONUSA_counter(j) = 1; 
        junk_title(c) = title(j); 
        junk_first(c) = first(j); 
        junk_last(c) = last(j); 
        junk_affiliation(c) = affiliation(j); 
        junk_institution(c) = institution(j); 
        junk_year(c) = year(j); 
    end 
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end 
  
%deletes data where appropriate 
  
%convert to logical indexing format 
NONUSA_counter = NONUSA_counter == 1; 
  
%apply conditions 
title(NONUSA_counter,:) = []; 
year(NONUSA_counter,:) = []; 
first(NONUSA_counter,:) = []; 
last(NONUSA_counter,:) = []; 
affiliation(NONUSA_counter,:) = []; 
institution(NONUSA_counter,:) = []; 
%% 5. Data Output 
  
%create the headings for excel data: 
heading = strings(1,6); 
heading(1) = 'Article Title'; 
heading(2) = 'Year'; 
heading(3) = 'Last Name'; 
heading(4) = 'First Name'; 
heading(5) = 'Affiliation'; 
heading(6) = 'Institution'; 
  
final_data = horzcat(title, year, last, first, affiliation, 
institution); 
final_data = vertcat(heading,final_data); 
xlswrite(excel, final_data); 
  
NON_USA_data = horzcat(junk_title, junk_year, junk_last, junk_first, 
... 
    junk_affiliation, junk_institution); 
NON_USA_data = vertcat(heading,NON_USA_data); 
xlswrite(NONUSA_excel, NON_USA_data); 
  
toc 
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